Rozanne C de Veer
Overview
Explore the profile of Rozanne C de Veer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Veer R, van Hooff M, Werner E, Beuers U, Drenth J, Cuperus F, et al.
JHEP Rep
. 2024 Aug;
6(8):101132.
PMID: 39113899
Background & Aims: Although primary biliary cholangitis (PBC) is considered a rare disorder, accurate determination of its incidence and prevalence remains challenging due to limited comprehensive population-based registries. We aimed...
2.
van Hooff M, de Veer R, Karam V, Adam R, Taimr P, Polak W, et al.
JHEP Rep
. 2024 Jul;
6(8):101100.
PMID: 39045337
Background & Aims: Tacrolimus has been associated with recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT), which in turn may reduce survival. This study aimed to assess the...
3.
de Veer R, van Hooff M, da Silva G, Harms M, Metselaar H, Willemse J, et al.
Hepatol Res
. 2023 Jan;
53(5):401-408.
PMID: 36635224
Aim: This study aims to assess the health-related quality of life (HRQoL) in a Dutch population of patients with primary biliary cholangitis (PBC) in relation to the prognosis and need...
4.
de Veer R, van Hooff M, Corpechot C, Thorburn D, Invernizzi P, Lammers W, et al.
Am J Gastroenterol
. 2023 Jan;
118(7):1196-1203.
PMID: 36621963
Introduction: Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (ΔGLOBE) and liver transplantation (LT)-free survival...
5.
de Veer R, Harms M, Corpechot C, Thorburn D, Invernizzi P, Janssen H, et al.
Aliment Pharmacol Ther
. 2022 Sep;
56(9):1408-1418.
PMID: 36138566
Background: After 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels. Aim: To assess the...
6.
de Veer R, da Silva G, van Hooff M, Harms M, Metselaar H, Willemse J, et al.
BMJ Open Gastroenterol
. 2021 Dec;
8(1).
PMID: 34916226
Objective: Patients with primary biliary cholangitis (PBC) have an impaired health-related quality of life (HRQoL). Practice guidelines recommend evaluating the HRQoL in all patients with PBC. The aim of this...
7.
Kreijne J, de Vries A, de Veer R, Bouma G, Dijkstra G, Voskuil M, et al.
Aliment Pharmacol Ther
. 2020 Apr;
51(12):1353-1364.
PMID: 32342997
Background: To timely detect myelotoxicity and hepatotoxicity, laboratory monitoring at 3-month intervals is advised throughout thiopurine maintenance treatment for IBD. However, reported incidence rates of myelotoxicity and hepatotoxicity in maintenance...
8.
Laschtowitz A, de Veer R, van der Meer A, Schramm C
United European Gastroenterol J
. 2020 Apr;
8(6):667-674.
PMID: 32299307
Primary biliary cholangitis is a cholestatic, chronic autoimmune liver disease with a wide individual variation in disease progression. The diagnosis is predominantly based on chronic elevation of alkaline phosphatase and...
9.
Harms M, de Veer R, Lammers W, Corpechot C, Thorburn D, Janssen H, et al.
Gut
. 2019 Dec;
69(8):1502-1509.
PMID: 31843787
Objective: The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number...
10.
Kreijne J, de Veer R, de Boer N, Dijkstra G, West R, Moorsel S, et al.
Aliment Pharmacol Ther
. 2019 Jul;
50(4):407-415.
PMID: 31359480
Background: Low-dose thiopurine-allopurinol (LDTA) combination therapy is a commonly applied optimisation strategy in IBD patients with a skewed thiopurine metabolism. Aim: To assess continued LDTA maintenance treatment at annual intervals...